RESUMEN
One-hundred-and-thirty normally menstruating females were subgrouped equally and enrolled from the family planning clinic to study the clinical performance of the monthly injectable contraceptives medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg (Cycloprovera) and norethisterone enanthate 50 mg + estradiol valerate 5 mg (HRP-102) and their effects on some metabolic parameters. The contraceptive efficacy after 6 months of use for both drugs was 100%. No change in menstrual pattern occurred in 74% of Cycloprovera users and 67.3% of HRP-102 users. A statistically significant decrease (P less than 0.01) occurred in HDL-cholesterol and total serum protein values and a statistically significant increase (P less than 0.01) was observed in hematocrit value of Cycloprovera users only. Body weight and blood pressure values after 6 months of drug use showed no statistically significant changes in both groups. Also, no statistically significant changes were noticed in both groups for hemoglobin, post-prandial blood glucose, cholesterol, A/G ratio, SGPT and SGPT values following 6 months of injectable contraceptive use. None of the injectable users developed cervical dysplastic changes cytologically.
Asunto(s)
Anticonceptivos Femeninos/administración & dosificación , Estradiol/análogos & derivados , Acetato de Medroxiprogesterona , Medroxiprogesterona/análogos & derivados , Noretindrona/análogos & derivados , Alanina Transaminasa/sangre , Aspartato Aminotransferasas/sangre , Proteínas Sanguíneas/metabolismo , Peso Corporal/efectos de los fármacos , Ensayos Clínicos como Asunto , Anticonceptivos Orales Combinados/administración & dosificación , Anticonceptivos Orales Combinados/efectos adversos , Anticonceptivos Orales Combinados/farmacología , Combinación de Medicamentos , Estradiol/administración & dosificación , Estradiol/efectos adversos , Estradiol/farmacología , Femenino , Humanos , Inyecciones Intramusculares , Lípidos/sangre , Medroxiprogesterona/administración & dosificación , Medroxiprogesterona/efectos adversos , Medroxiprogesterona/farmacología , Menstruación/efectos de los fármacos , Noretindrona/administración & dosificación , Noretindrona/efectos adversos , Noretindrona/farmacologíaRESUMEN
The presence of aerobic and anaerobic bacteria, yeasts and mycoplasma/ureaplasma was investigated in seventeen women before and after six months use of a contraceptive vaginal ring releasing levo-Norgestrel and estradiol and in 16 women using an oral contraceptive containing levo-Norgestrel and ethinylestradiol. Apart from an increase in yeasts in both groups, no significant changes in the vaginal bacteriology could be found. Vaginal smears were examined before and during treatment for up to two years in a group of 120 women participating in a clinical trial of the contraceptive vaginal ring. No changes in the squamous epithelium or cylinder cells were found. The amount of leucocytes increased in the smears. The results indicate that use of the contraceptive vaginal ring does not affect the bacterial ecology of the vagina. The increase in leucocytes indicates a weak inflammatory reaction which might explain the increase in vaginal discharge often observed by women using the contraceptive vaginal ring.